July 4, 2020 23:57
تغيير حجم الخط
Hemlibra® (Emicizumab) and it’s known interaction with certain laboratory assays in patients who become infected with the novel corona virus that causes COVID-19
Megamox® 625mg tablets is associated with a typographic error in the units for the weight of the product stated on the aluminum foil.
XELJANZ (tofacitinib): increased risk of venous thrombo-embolism and increased risk of serious and fatal infections
Update on instruction for the preparation of Curam® (Amoxicillin Clavulanic Acid POS - powder for Oral Suspension) bottles
Ecalta 100mg Powder for Concentrate for Solution for Infusion (Anidulafungin): Solution for Infusion must no longer be frozen
Hydrochlorothiazide - Risk of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma)
Restriction of combined use of medicines affecting the renin-angiotensin aldosterone system (RAAS) for medicinal products containing Olmepress (Olmesartan).
Kyprolis (carfilzomib) – New Safety Information: Risk of Progressive Multifocal Leukoencephalopathy (PML) and Hepatitis B Virus (HBV) Reactivation
Important Safety Update on ESBRIET® (pirfenidone) and Drug-Induced Liver Injury (DILI)
FEGONA (fingolimod) – New contraindication in pregnant women and in women of childbearing potential not using effective contraception